...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Applied Microbiology and Biotechnology >Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface
【24h】

Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface

机译：使用在其表面显示E7抗原的非转基因乳酸菌对小鼠乳头瘤病毒16型诱导的肿瘤的保护

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Human papillomavirus (HPV) is the causative agent of cervical cancer (CxCa) and the most commonly sexually transmitted pathogen worldwide. HPV type 16 (HPV-16) E7 oncoprotein is constitutively produced in CxCa and considered as a good antigen candidate for the development of new therapeutic CxCa vaccines. Here, we report the use of non-genetically modified, E7-expressing lactic acid bacteria (LAB) by using the cell-binding domain from Lactobacillus casei A2 phage lysin as a cell wall anchor. The versatility of this system was validated by investigating E7 stability at the surface of Lactococcus lactis and L. casei, two major species of LAB. Moreover, we demonstrated the successful use of these LAB displaying E7 antigen as a mucosal live vaccine in mice. Altogether, these results show the feasibility of using non-genetically modified LAB for low-cost mucosal immunotherapy against HPV-related CxCa in humans.
机译：人乳头瘤病毒（HPV）是宫颈癌（CxCa）的病原体，也是全世界最常见的性传播病原体。 HPV 16型（HPV-16）E7癌蛋白在CxCa中组成性产生，被认为是开发新型治疗性CxCa疫苗的良好候选抗原。在这里，我们报告通过使用干酪乳杆菌A2噬菌体溶素的细胞结合域作为细胞壁锚定，使用非基因修饰的，表达E7的乳酸菌（LAB）。该系统的多功能性通过研究乳酸菌乳酸球菌和干酪乳杆菌（乳酸菌的两个主要种类）表面的E7稳定性来验证。此外，我们证明了这些展示E7抗原的LAB作为小鼠粘膜活疫苗的成功应用。总而言之，这些结果表明使用非基因修饰的LAB进行低成本黏膜免疫疗法治疗人类HPV相关CxCa的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号